Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Short term Debt (2016 - 2018)

Historic Short term Debt for Niagen Bioscience (NAGE) over the last 3 years, with Q4 2018 value amounting to $137000.0.

  • Niagen Bioscience's Short term Debt fell 5580.65% to $137000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $137000.0, marking a year-over-year decrease of 5580.65%. This contributed to the annual value of $137000.0 for FY2018, which is 5580.65% down from last year.
  • As of Q4 2018, Niagen Bioscience's Short term Debt stood at $137000.0, which was down 5580.65% from $310000.0 recorded in Q4 2017.
  • Niagen Bioscience's Short term Debt's 5-year high stood at $1.5 million during Q1 2016, with a 5-year trough of $137000.0 in Q4 2018.
  • For the 3-year period, Niagen Bioscience's Short term Debt averaged around $579894.5, with its median value being $327000.0 (2016).
  • In the last 5 years, Niagen Bioscience's Short term Debt tumbled by 7749.54% in 2016 and then crashed by 988.37% in 2017.
  • Quarter analysis of 3 years shows Niagen Bioscience's Short term Debt stood at $344000.0 in 2016, then decreased by 9.88% to $310000.0 in 2017, then plummeted by 55.81% to $137000.0 in 2018.
  • Its Short term Debt stands at $137000.0 for Q4 2018, versus $310000.0 for Q4 2017 and $344000.0 for Q4 2016.